8-K Announcements
6Material company update
Jun 22, 2026·SEC
Material company update
Apr 7, 2026·SEC
Material company update
Feb 13, 2026·SEC
Nutriband Inc.(NTRB)Earnings, Financials & Key Ratios
NTRB•NASDAQ
$3.03
Price updated Jul 7, 2026
AboutNutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. Nutriband Inc. has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices. The company was incorporated in 2016 and is headquartered in Orlando, Florida.Show more
- Revenue$2M-4.8%
- EBITDA-$8M-26.8%
- Net Income-$8M+21.5%
- EPS (Diluted)-2.58-160.6%
- Gross Margin25.68%-21.4%
- EBITDA Margin-398.9%-33.3%
- Operating Margin-408.41%-30.6%
- Net Margin-404.08%+17.5%
- ROE-125.56%+22.9%
NTRB Price & Volume
Nutriband Inc. (NTRB) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operating Losses Threaten Clinical Development Runway
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical and liquidity binary
Key Thesis Takeaways
- Nutriband faces a precarious financial outlook characterized by volatile revenue streams and a structural inability to achieve profitability, as evidenced by a TTM operating margin of -408.41%.
- The company's reliance on external capital to fund its AVERSA program is underscored by a consistent erosion of equity, with retained earnings reaching -$47.9M as of 2026Q1.
- Investors should remain cautious regarding the firm's long-term viability, as current cash reserves of $4.0M appear insufficient to sustain the high R&D and SG&A overhead required for its clinical-stage pipeline.
Verdict Logic
the company's inability to generate positive free cash flow, coupled with a 2026Q1 cash position of only $4.0M against significant R&D requirements, suggests a high risk of further shareholder dilution.
NTRB Growth Metrics
Nutriband Inc. (NTRB) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years16.63%
3 Years-0.69%
TTM-24.84%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM18.95%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-191.07%
Return on Capital
10 Years-355.09%
5 Years-74.65%
3 Years-97.47%
Last Year-125.55%
Peers Comparison
Key metrics vs top competitors for Nutriband Inc. (NTRB)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $3.03 | $36.83M | -1.17 | -4.83% | -404.08% | -125.56% | — | |
| $2.05 | $29.77M | -1.71 | 10429.36% | -1038.77% | — | — | |
| $21.64 | $2.1B | -42.43 | 504.79% | -0.11% | -0.33% | — | |
| $18.57 | $774.93M | -649.30 | 6.85% | 0.24% | 0.42% | — | |
| $2.70 | $8.62M | -0.32 | — | — | -264.79% | — | |
| $11.19 | $1.55B | -1.09 | -2.75% | -43.5% | -50.65% | — |
Compare NTRB vs Peers
Nutriband Inc. (NTRB) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
NTRB SEC Filings & Documents
Nutriband Inc. (NTRB) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when NTRB posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
NTRB Frequently Asked Questions
Nutriband Inc. (NTRB) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Nutriband Inc.'s revenue?
Nutriband Inc. (NTRB) reported $1.8M in revenue for fiscal year 2025.
How fast is Nutriband Inc. growing?
Nutriband Inc. (NTRB) saw revenue decline by 4.8% over the past year.
Is NTRB profitable?
Nutriband Inc. (NTRB) reported a net loss of $8.1M for fiscal year 2025.
Dividend & Returns
What is NTRB's return on equity?
Nutriband Inc. (NTRB) has a return on equity (ROE) of -125.6%. Negative ROE indicates the company is unprofitable.
What is Nutriband Inc.'s free cash flow?
Nutriband Inc. (NTRB) had negative free cash flow of $4.4M in fiscal year 2025, likely due to heavy capital investments.